27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Study-level data from 14 studies, 2,310,330 individuals, and 102,174 dementia case patients were included. 3 key findings →
Design: meta-analysis Participants: 2,310,330 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
General cognitive function is substantially heritable across the human life course from adolescence to old age. 5 key findings →
Design: meta-analysis Participants: 53,949 Evidence: high
Full summary, score breakdown and related studies → Original source
Modifiable vascular and lifestyle-related risk factors have been associated with dementia risk in observational studies. 4 key findings →
Design: randomized controlled trial Participants: 631 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOE genotype, and presence of cognitive impairment. 4 key findings →
Design: meta-analysis Participants: 2,914 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Memantine monotherapy improved cognition, behavior, activities of daily living, global function, and stage of dementia and was well-tolerated by AD patients. 5 key findings →
Design: meta-analysis Participants: 2,433 Evidence: high
Full summary, score breakdown and related studies → Original source
Epidemiologic studies suggest that a Mediterranean diet, an antioxidant-rich cardioprotective dietary pattern, delays cognitive decline, but clinical trial evidence is lacking. 5 key findings →
Design: RCT Participants: 447 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The likelihood of amyloid positivity was associated with age and APOE ε4 status. 3 key findings →
Design: meta-analysis Participants: 377 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among sedentary older adults, a 24-month moderate-intensity physical activity program compared with a health education program did not result in improvements in global or domain-specific cognitive function. 5 key findings →
Participants: 818 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Resveratrol was safe and well-tolerated. 4 key findings →
Design: clinical trial Participants: 119 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The objective of this meta-analysis was to determine the association of the apolipoprotein E ( ApoE ) gene with exceptional longevity (EL) ( i.e ., reaching 100+ years) by identifying possible unequal distribution of alleles/genotypes in the common variants ε2, ε3, and ε4 among centenarians and younger population. 4 key findings →
Design: meta-analysis Participants: 2,776 Evidence: high
Full summary, score breakdown and related studies → Original source
APOE ɛ4, the most significant genetic risk factor for Alzheimer disease (AD), may mask effects of other loci. 5 key findings →
Design: meta-analysis Participants: 4,203 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Though still small, the current body of RCT evidence indicates that CT is safe and modestly effective on cognition in patients with mild to moderate PD. 4 key findings →
Participants: 272 Evidence: high
Full summary, score breakdown and related studies → Original source
Lower intakes of nutrient-dense foods and higher intakes of unhealthy foods are each independently associated with smaller left hippocampal volume. 3 key findings →
Design: meta-analysis Participants: 255 Evidence: high
Full summary, score breakdown and related studies → Original source
The most common anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and bladder antimuscarinics. 4 key findings →
Design: cohort study Participants: 3,434 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Points• UK Biobank is a very large and detailed prospective study with over 500,000 participants aged 40-69 years when recruited in 2006-2010.• The study has collected and continues to collect extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometry, multimodal imaging, genome-wide genotyping and longitudinal follow-up for a wide range of health-related outcomes.• Wide consultation; input from scientific, management, legal, and ethical partners; and industrial-scale, centralised processes have been essential to the development of this resource.• UK Biobank is available for open access, without the need for collaboration, to any bona fide researcher who wishes to use it to conduct health-related research for the benefit of the public. 1 key finding →
Design: case-control study Participants: 500,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) in Parkinson's disease (PD) may be associated with subtle functional impairment and worse quality of life. 4 key findings →
Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
Statin therapy was not associated with cognitive impairment in RCTs. 5 key findings →
Design: meta-analysis Participants: 46,836 Evidence: high
Full summary, score breakdown and related studies → Original source
Four-week changes in NPI-Q total scores did not differ significantly between the treatment and placebo groups. 5 key findings →
Participants: 12 Evidence: high
Full summary, score breakdown and related studies → Original source
With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. 3 key findings →
Design: clinical trial Participants: 93 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Main results Seventeen trials with 1067 participants met the inclusion criteria. 5 key findings →
Design: meta-analysis Participants: 1,067 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Patients with MCI with APOEε4, abnormal CSF τ level, hippocampal and medial temporal lobe atrophy, entorhinal atrophy, depression, diabetes, hypertension, older age, female gender, lower MMSE score and higher ADAS-cog score, had a high risk for the progression to AD. 1 key finding →
Design: meta-analysis Participants: 14,821 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A rare variant in TREM2 (p.R47H, rs75932628) was recently reported to increase the risk of Alzheimer's disease (AD) and, subsequently, other neurodegenerative diseases, i.e. frontotemporal lobar degeneration (FTLD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). 4 key findings →
Design: meta-analysis Participants: 828 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial. 4 key findings →
Participants: 86 Evidence: high
Full summary, score breakdown and related studies → Original source
This Finnish randomized controlled trial was the first large study to show that a two-year program combining diet counseling, exercise, cognitive training, and monitoring of heart-health risk factors could help maintain or improve thinking skills in older adults at elevated dementia risk, compared with a control group who received only general health advice. 3 key findings →
Design: RCT Participants: 1,260 Evidence: high
Full summary, score breakdown and related studies → Original source
Avagacestat did not demonstrate efficacy and was associated with adverse dose-limiting effects. 5 key findings →
Design: randomized controlled trial Participants: 263 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →